{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:25:29Z","timestamp":1768278329953,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["2023KJ032"],"award-info":[{"award-number":["2023KJ032"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022MH069"],"award-info":[{"award-number":["ZR2022MH069"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103983"],"award-info":[{"award-number":["82103983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioorg.2025.108293","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:32:44Z","timestamp":1740076364000},"page":"108293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13"],"prefix":"10.1016","volume":"157","author":[{"given":"Liang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanbo","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108293_bb0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bioorg.2025.108293_bb0010","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.2174\/0929867326666190816230650","article-title":"Small molecular gemcitabine prodrugs for Cancer therapy","volume":"27","author":"Miao","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0020","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/jm901181h","article-title":"Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine","volume":"52","author":"Bender","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0025","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1021\/acs.jmedchem.3c00006","article-title":"Design, synthesis, and anti-Cancer evaluation of novel cyclic phosphate prodrug of gemcitabine","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0030","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1016\/j.bmc.2016.09.033","article-title":"Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity","volume":"24","author":"Jiang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0035","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12032-020-01386-6","article-title":"NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials","volume":"37","author":"Kapacee","year":"2020","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0045","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1021\/acs.jmedchem.0c02194","article-title":"Single Diastereomers of the clinical anticancer ProTide agents NUC-1031 and NUC-3373 preferentially target Cancer stem cells in vitro","volume":"64","author":"Slusarczyk","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0050","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00280-020-04079-z","article-title":"Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer","volume":"85","author":"Arora","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/med.20044","article-title":"Aminopeptidase-N\/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects","volume":"26","author":"Bauvois","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108293_bb0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.molmed.2008.06.003","article-title":"The moonlighting enzyme CD13: old and new functions to target","volume":"14","author":"Mina-Osorio","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108293_bb0065","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/biomedicines11030724","article-title":"The role of the Ectopeptidase APN\/CD13 in Cancer","volume":"11","author":"Lendeckel","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.108293_bb0070","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.3390\/ijms23179813","article-title":"Aminopeptidase N inhibitors as pointers for overcoming antitumor treatment resistance","volume":"23","author":"Farsa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108293_bb0075","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1172\/JCI42550","article-title":"CD13 is a therapeutic target in human liver cancer stem cells","volume":"120","author":"Haraguchi","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108293_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/ijo.2016.3496","article-title":"A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma","volume":"49","author":"Yamashita","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.660377","article-title":"Suppression of CD13 enhances the cytotoxic effect of chemotherapeutic drugs in hepatocellular carcinoma cells","volume":"12","author":"Ji","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3727\/096504020X15919605976853","article-title":"CD13: a key player in multidrug resistance in Cancer chemotherapy","volume":"28","author":"Guo","year":"2020","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bioorg.2025.108293_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02174207","article-title":"Clinical trials of bestatin for leukemia and solid tumors","volume":"4","author":"Ota","year":"1992","journal-title":"Biotherapy"},{"key":"10.1016\/j.bioorg.2025.108293_bb0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejmech.2016.05.068","article-title":"Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent","volume":"121","author":"Jiang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3389\/fphar.2018.01042","article-title":"CD13 inhibition enhances cytotoxic effect of chemotherapy agents","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0110","first-page":"2487","article-title":"CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3\/FAK\/NF-\u03baB pathway in gastric cancer cells, Transl","volume":"11","author":"Xiu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108293_bb0115","first-page":"2823","article-title":"Ubenimex suppresses glycolysis mediated by CD13\/hedgehog signaling to enhance the effect of cisplatin in liver cancer, Transl","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108293_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.18632\/aging.102598","article-title":"Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13\/EMP3\/PI3K\/AKT\/NF-\u03baB axis","volume":"12","author":"Guo","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bioorg.2025.108293_bb0125","first-page":"100048","volume":"2","author":"Jia","year":"2024","journal-title":"Targeted drug conjugates in Cancer therapy: challenges and opportunities, pharmaceutical science Advances."},{"key":"10.1016\/j.bioorg.2025.108293_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-020-00865-7","article-title":"CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110","volume":"13","author":"Dom\u00ednguez","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/med.20238","article-title":"Targeted drug delivery and penetration into solid tumors","volume":"32","author":"Corti","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108293_bb0140","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/cancers12061488","article-title":"First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumors: results of a phase I dose-escalation study","volume":"12","author":"Schliemann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108293_bb0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2017.11.074","article-title":"Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy","volume":"143","author":"Jiang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0150","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3892\/ijo.2017.4159","article-title":"BC-02 eradicates liver cancer stem cells by upregulating the ROS-dependent DNA damage","volume":"51","author":"Dou","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108293_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105343","article-title":"Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy","volume":"116","author":"Yue","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108293_bb0160","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.3390\/molecules28176343","article-title":"Discovery of a novel Ubenimex derivative as a first-in-class dual CD13\/proteasome inhibitor for the treatment of Cancer","volume":"28","author":"Zhang","year":"2023","journal-title":"Molecules"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T21:38:02Z","timestamp":1763847482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S0045206825001737"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108293","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108293"}}